Stathmin is overexpressed in malignant mesothelioma

Anticancer Research

Volumn 27, Issue 1 A, 2007, Pages 39-44

  Kim, Jae Y ^a,b   Harvard, Chansonette ^a   You, Liang ^a   Xu, Zhidong ^a   Kuchenbecker, Kristopher ^a   Baehner, Rick ^b   Jablons, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

LAP18; Mesothelioma; Metablastin; Oncoprotein 18; Op18; Phosphoprotein 19; Stathmin

Indexed keywords

STATHMIN;

ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; GENE ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CELL LINE, TUMOR; DNA, COMPLEMENTARY; HUMANS; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STATHMIN;

EID: 33847636750     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Pisick E and Salgia R: Molecular biology of malignant mesothelioma: a review. Hematol Oncol Clin North Am 19: 997-1023, 2005.
2. Bang KM, Pinheiro GA, Wood JM and Syamlal G: Malignant mesothelioma mortality in the United States, 1999-2001. Int J Occup Environ Health 12: 9-15, 2006.
3. Hodgson JT, McElvenny DM, Darnton AJ, Price MJ and Peto J: The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 92: 587-593, 2005.
4. Peto J, Hodgson JT, Matthews FE and Jones JR: Continuing increase in mesothelioma mortality in Britain. Lancet 345: 535-539, 1995.
5. Robinson BW and Lake RA: Advances in malignant mesothelioma. N Engl J Med 353: 1591-1603, 2005.
6. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y and Vogelzang NJ: Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113: 723-731, 1998.
7. Robledo R and Mossman B: Cellular and molecular mechanisms of asbestos-induced fibrosis. J Cell Physiol 180: 158-166, 1999.
8. Roggli VL, Sharma A, Butnor KJ, Sporn T and Vollmer RT: Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases. Ultrastruct Pathol 26: 55-65, 2002.
9. Papp T, Schipper H, Pemsel H, Bastrop R, Muller KM, Wiethege T, Weiss DG, Dopp E, Schiffmann D and Rahman Q: Mutational analysis of N-ras, p53, p16INK4a, p14ARF and CDK4 genes in primary human malignant mesotheliomas. Int J Oncol 18: 425-433, 2001.
10. Robinson BW, Musk AW and Lake RA: Malignant mesothelioma. Lancet 366: 397-408, 2005.
11. Scagliotti GV and Novello S: State of the art in mesothelioma. Ann Oncol 16 Suppl 2: ii240-245, 2005.
12. Lee AY, He B, You L, Dadfarmay S, Xu Z, Mazieres J, Mikami I, McCormick F and Jablons DM: Expression of the secreted frizzled-related protein gene family is down-regulated in human mesothelioma. Oncogene 23: 6672-6676, 2004.
13. Gazdar AF and Carbone M: Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40. Clin Lung Cancer 5: 177-181, 2003.
14. Rubin CI and Atweh GF: The role of stathmin in the regulation of the cell cycle. J Cell Biochem 93: 242-250, 2004.
15. Iancu-Rubin C and Atweh GF: p27(Kip1) and stathmin share the stage for the first time. Trends Cell Biol 15: 346-348, 2005.
16. Baldassarre G, Belletti B, Nicoloso MS, Schiappacassi M, Vecchione A, Spessotto P, Morrione A, Canzonieri V and Colombatti A: p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 7: 51-63, 2005.
17. Brattsand G: Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br J Cancer 83: 311-318, 2000.
18. Curmi PA, Nogues C, Lachkar S, Carelle N, Gonthier MP, Sobel A, Lidereau R and Bieche I: Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours. Br J Cancer 82: 142-150, 2000.
19. Melhem R, Hailat N, Kuick R and Hanash SM: Quantitative analysis of Op18 phosphorylation in childhood acute leukemia. Leukemia 11: 1690-1695, 1997.
20. Chen G, Wang H, Gharib TG, Huang CC, Thomas DG, Shedden KA, Kuick R, Taylor JM, Kardia SL, Misek DE, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM and Beer DG: Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas. Mol Cell Proteomics 2: 107-116, 2003.
21. Yuan RH, Jeng YM, Chen HL, Lai PL, Pan HW, Hsieh FJ, Lin CY, Lee PH and Hsu HC: Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol, in press, 2006.
22. Price DK, Ball JR, Bahrani-Mostafavi Z, Vachris JC, Kaufman JS, Naumann RW, Higgins RV and Hall JB: The phosphoprotein Op18/stathmin is differentially expressed in ovarian cancer. Cancer Invest 18: 722-730, 2000.
23. Friedrich B, Gronberg H, Landstrom M, Gullberg M and Bergh A: Differentiation-stage specific expression of oncoprotein 18 in human and rat prostatic adenocarcinoma. Prostate 27: 102-109, 1995.
24. Jeha S, Luo XN, Beran M, Kantarjian H and Atweh GF: Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells. Cancer Res 56: 1445-1450, 1996.
25. Alli E, Bash-Babula J, Yang JM and Hait WN: Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res 62: 6864-6869, 2002.
26. Rosell R, Scagliotti G, Danenberg KD, Lord RV, Bepler G, Novello S, Cooc J, Crino L, Sanchez JJ, Taron M, Boni C, De Marinis F, Tonato M, Marangolo M, Gozzelino F, Di Costanzo F, Rinaldi M, Salonga D and Stephens C: Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22: 3548-3553, 2003.
27. Nishio K, Nakamura T, Koh Y, Kanzawa F, Tamura T and Saijo N: Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells. Cancer 91: 1494-1499, 2001.